For example, the ADC trastuzumab emtansine specifically delivers a microtubule inhibitor to human epidermal growth factor receptor 2 (HER2)-overexpressing cells and has demonstrated enhanced efficacy over trastuzumab alone in patients with HER2-positive breast cancer [106]. Here, ERBB2 is linked to breast carcinoma.